Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
The MagSi-NA Pathogens Kit from AMSBIO enables easy extraction of DNA and RNA from serum, plasma, oropharyngeal swab / nasopharyngeal swab, and any other respiratory samples for pathogen detection.
The kit is particularly suitable for total nucleic acid extraction for SARS-CoV-2 / COVID-19 detection, currently a major bottleneck in COVID-19 testing.
Due to the kit’s simple protocol and ready-to-use-agents, it is easy to scale to small, medium, and high-throughput automation, yielding highly pure nucleic acid in small elution volumes. The MagSi-NA Pathogens Kit utilizes magnetic beads to ensure a consistently high yield, with the proprietary MagSi-PA VII magnetic beads optimized for fast separation even from viscous sample lysates.
In less than 30 minutes, the MagSi-NA Pathogens Kit delivers consistently high yield of total nucleic acids, which can be used for qPCR-based or any other enzymatic pathogen detection method. The kit is compatible with liquid handling robots and protocols are available for popular magnetic processors enabling easy integration into a high-throughput workflow.
For further information on the MagSi-NA Pathogens Kit please visit http://www.amsbio.com/magsi-na-pathogen-kit.aspx or contact AMSBIO on +44-1235-828200 /+1-617-945-5033 / [email protected].
Founded in 1987, AMS Biotechnology(AMSBIO) is recognized today as a leading transatlantic company contributing tothe acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation.
This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.
